Werewolf Therapeutics, Inc. (HOWL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other ...
) has been revised to $6.38 / share. This is an increase of 20.19% from the prior estimate of $5.30 dated February 21, 2026. The price target is an average of many targets provided by analysts. The ...
Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Werewolf Therapeutics (HOWL – Research Report) yesterday and set a price target of $9.00. The company’s shares closed ...
Werewolf Therapeutics, Inc. (HOWL) stock price is 0.63 and Werewolf Therapeutics, Inc. (HOWL) 10-day simple moving average is 0.63. Werewolf Therapeutics, Inc. (HOWL) stock price is 0.63 and Werewolf ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results